The meta-analysis described above showed no clear increased risk of cancer recurrence, with an odds ratio (OR) of 0.57 (95% CI 0.31–1.02) for recurrence with growth hormone use compared to no use, but the OR for secondary cancer development was 1.34 (95% CI 0.92–1.96) (The OR presented in the text of the paper differs from that in the figure, and we confirmed that the OR shown here is correct by contacting the corresponding author). The gene discussed is GH1; the disease is cancer.